Cadrenal Therapeutics, Inc. · NASDAQ:CVKD
Cadrenal Therapeutics — Investor Presentation (May 2023)
32 slides from Cadrenal Therapeutics's investor presentation, May 2023
Slide 1: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. NASDAQ: CVKD May 2023 CREATE A COVER SLIDE 1
Slide 2: Cautionary Statement Concerning Forward Looking Statements
Cautionary Statement Concerning Forward Looking Statements This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projectio
Slide 3: Agenda
TECARAFIN OPPORTUNITY AGENDA MANAGEMENT, PRINCIPAL INVESTIGATOR & SCIENTIFIC ADVISORY BOARD UPCOMING MILESTONES CLINICAL DATA 3
Slide 4: Tecarfarin Investment Case
CADRENAL Investment Case There are UP TO Peak U.S. annual market potential CADRENAL NO EFFECTIVE $1B for tecarfarin for orphan indication1 THERAPEUTICS’ TREATMENT $90M Invested to date asset, OPTIONS for 11 Clinical trials tecarfarin patients with ESRD + AFib >1,000 Subjects POSITIONED FOR FINAL, CO
Slide 5: Tailored Regulatory Pathway for Patients with ESRD + AFib
Tailored Regulatory Pathway for Patients with ESRD + AFib Cadrenal intends to follow the FDAs guidance (which granted tecarfarin orphan drug designation and subsequently granted Fast Track Designation) and that of industry leading cardiologists and nephrologists to pursue approval for tecarfarin in
Slide 6: The Problem: No effective anticoagulant treatment options
THE PROBLEM No effective ESRD + AFib anticoagulant treatment options for patients with End-Stage Renal Disease AND Atrial Fibrillation 6
Slide 7: No effective treatment options for patients with ESRD + AFib
T H E P R O B L E M | No effective treatment options for patients with ESRD + AFib The presence of either chronic kidney disease (CKD) or AFib increases the risk of serious thromboembolic adverse clinical outcomes, such as stroke and death Increased Stroke Risk Due to AFib the most common arrhythmia
Slide 8: Antithrombotic therapy is typically recommended to decrease stroke risk in AFib
T H E P R O B L E M | No effective treatment options for patients with ESRD + AFib Antithrombotic therapy is typically recommended to decrease this risk of stroke in AFib patients Warfarin Treatment In normal kidney and Stroke Risk function, warfarin AFib patients REDUCES stroke Antithrombotic risk
Slide 9: Warfarin is difficult to control in ESRD patients
T H E P R O B L E M | No effective treatment options for patients with ESRD + AFib Warfarin (most common treatment) is difficult to control in ESRD patients due to metabolism via cytochrome P450 pathway1 Lower TTR (<60%) across lower eGFR strata2 50 GFR <30 40 Time severely OUTSIDE of therapeutic ra
Slide 10: Most patients with ESRD + AFib are not anticoagulated
T H E P R O B L E M | No effective treatment options for patients with ESRD + AFib Despite the significantly increased risk of stroke in ESRD with AFib, most patients are not given warfarin due to the lack of evidence of benefit Use of warfarin in ESRD + AFib Patients1 (N=9,974)1 (N=47,480)2 100% 80
Slide 11: Our Solution: Tecarfarin
OUR SOLUTION Tecarfarin PHASE 3, FAVORABLE SAFETY PROFILE Different metabolic • Established similar MOA to warfarin pathway • Elimination from body was not affected by TARGETS than the most commonly prescribed severe kidney dysfunction drugs for the treatment of thrombosis • Demonstrated TTR > 72% v
Slide 12: Randomized Trial Shows Tecarfarin Well-Tolerated for Stroke and Thrombus Prevention
OUR SOLUTION 600 Patient Randomized Controlled Trial Shows Tecarfarin is Well-Tolerated for Stroke and Thrombus Prevention, with Fewer Hemorrhagic Events Tecarfarin had Tecafarin Warfarin fewer thrombotic events compared to warfarin 2 2 Randomized, double- blind clinical trial 1 N=607 0 0 0 Patients
Slide 13: Tecarfarin is Designed to be an Improvement to Warfarin
OUR SOLUTION Tecarfarin is Designed to be an Improvement to Warfarin Tecarfarin was as Percent Time in Therapeutic Range Based on Interpolated INR effective as warfarin in patients with normal 100 ∆ = 0.8% renal function 90 Time in Therapeutic Range (%) 80 71.5 72.3 70 60 Randomized, double- 50 blin
Slide 14: Renal Failure Had a Significant Impact on Warfarin PK vs Tecarfarin
OUR SOLUTION Renal Failure Had a Significant Impact on Warfarin PK vs Tecarfarin Percent Increase in Exposure for Healthy Volunteer Subjects vs. Chronic Kidney Disease Subjects for (S)-Warfarin and Tecarfarin (n =23) 50 AUC 25 t1/2 45 20 40 44 20 Percent Increase/Decrease 35 15 Percent Increase 30 1
Slide 15: Agenda
TECARAFIN OPPORTUNITY AGENDA MANAGEMENT, PRINCIPAL INVESTIGATOR & SCIENTIFIC ADVISORY BOARD UPCOMING MILESTONES CLINICAL DATA 15
Slide 16: Management
Management Quang Pham Douglas Losordo, MD Matthew Szot, CPA CEO & Founder Chief Medical Officer Chief Financial Officer Espero BioPharma Cardiologist, Global Head of R&D S&W Seed Company (NASDAQ: SANW), CFO Lathian Systems Director, Longeveron, Inc. (NASDAQ: LGVN) INVO Bioscience (NASDAQ: INVO), Gen
Slide 17: Principal Investigator and Scientific Advisory Board
Principal Investigator and Scientific Advisory Board (SAB) SCI ENTI FI C ADVI SORY BOARD Christopher Granger, MD Professor of Medicine in the Division of Cardiology at Duke University Member, Duke Clinical Research Institute (DCRI) Elaine M. Hylek, MD, MPH Professor of Medicine, Boston University Sc
Slide 18: Agenda
TECARAFIN OPPORTUNITY AGENDA MANAGEMENT, PRINCIPAL INVESTIGATOR & SCIENTIFIC ADVISORY BOARD UPCOMING MILESTONES CLINICAL DATA 18
Slide 19: Planned Phase 3 Study
Planned Phase 3 Study o ACTOR-AF Study Anti-Coagulation with Tecarfarin on Outcomes in Renal Disease and Atrial Fibrillation Expected to be the o Phase 3 | 492 patients FINAL STUDY required to seek regulatory approval o Randomized, Double-Blind, Placebo-Controlled Outcomes Study – Tecarfarin vs. Pla
Slide 20: Tecarfarin Phase 3 Trial Design
Tecarfarin Phase 3 Trial Design Tecarfarin vs. Placebo in Patients with ESRD and AFib Randomized, Double-Blind, Placebo-Controlled (no active control) Planned Enrollment N = 492 12-month follow-up Tecarfarin (n = 246) for Primary Endpoint of time to ESRD (eGFR < 15 mL/min/1.73 mm2) R combined endpoi
Slide 21: $1 Billion U.S. Annual Market Potential
U.S. ANNUAL MARKET POTENTIAL ESRD + AFib 1 BILLION* UP TO $ if approved by the FDA Orphan Pricing $65 per day (WAC) | $23,400 annually *Based upon 2019 study, adjusted for inflation 21
Slide 22: Targeted Patient Commercialization Opportunity
Targeted Patient Commercialization Opportunity Addressable patient Fresenius and DaVita operate 70% of the 6,800 70% population occurs at DaVita or Fresenius outpatient dialysis centers in the U.S. on a combined Dialysis Centers basis Once advancing to ESRD: patients with ESRD+AFib receive dialysis
Slide 23: Tafamidis: Cardiovascular Orphan Drug Case Study
Tafamidis: Cardiovascular Orphan Drug Case Study Developed by FoldRx with $88 million in private financing, before FoldRx was subsequently acquired by Pfizer VYNDAQEL® (tafamidis meglumine) and VYNDAMAX® (tafamidis) are novel oral cardiovascular drugs FDA Orphan Drug, Fast Track, Priority Review & B
Slide 24: Cap Table & Insider Ownership
Cap Table & Insider Ownership Cap Table Insider Ownership (Common Stock) Cash (3/31/23) $4.0 million Named Executive Officers and Directors Debt NONE Quang Pham, CEO Common Shares Outstanding 11,722,754 6,300,000 Preferred Shares Outstanding NONE Matthew Szot, CFO 500,000 Warrants - Underwriter 110,
Slide 25: Summary of Highlights
Summary of Highlights PORTFOLIO R&D o Phase 3 orphan drug candidate o Retrometabolic design eliminates with IP rights in North America, or minimizes the CYP450 Europe, Australia, Asia and Africa metabolism in the liver ADVANTAGE o 7-year U.S. orphan drug marketing exclusivity potential upon orphan d
Slide 26: Contact Us
C O N TA C T U S Quang Pham Matthew Szot CEO & Founder CFO 26
Slide 27: Agenda
TECARAFIN OPPORTUNITY AGENDA MANAGEMENT, PRINCIPAL INVESTIGATOR & SCIENTIFIC ADVISORY BOARD UPCOMING MILESTONES CLINICAL DATA 27
Slide 28: Retrometabolic Drug Design
Retrometabolic Drug Design Goal is to reduce risk Novel therapeutic agent with a of potential off-target proven mechanism of action and undesired side and cleaner metabolic profile effects Tecarfarin design: Metabolic clearance not hindered by the body by eliminating or minimizing its metabolism in
Slide 29: Tecarfarin Phase 1 PK Trial in Stage 4 CKD Patients
Tecarfarin Phase 1 PK Trial in Stage 4 CKD Patients Summary Table Result Highlights % change between Stage 4 CKD patients vs healthy subjects matched for each drug using a randomized Tecarfarin Warfarin crossover design (n=23) Elimination from the Exposure increased 44% body was not affected in Stag
Slide 30: Tecarfarin Shows TTR Above Anticoagulation Control Threshold
Tecarfarin Shows TTR Above Anticoagulation Control Threshold o Tecarfarin vs warfarin trial Tecarfarin percent time in therapeutic range (TTR) o Randomized, double-blind trial designed to Phase 2/3 compare the quality of anticoagulation 100% 76.5% Trial o Average TTR as measured by the International
Slide 31: Risk Factors Related to Our Business
Risk Factors Related to Our Business Our business is subject to o Our success is primarily dependent on the successful regulatory approval and commercialization of several risks you should be our lead product candidate aware of before making an o Our approach to discovery and development is novel, u
Slide 32: Glossary of Terms
Glossary of Terms Term Abbreviation Atrial Fibrillation AFib Area Under the Curve AUC Chronic Kidney Disease CKD Maximum Serum Concentration Cmax Chemistry, Manufacturing and Controls CMC End Stage Renal Disease ESRD Half Life t1/2 International Normalized Ratio INR Journal of the American Medical A
Cadrenal Therapeutics — Investor Presentation (May 2023) on 6ix